Resmed (RME) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RME Analyst Ratings

Moderate Buy

4 Buy

10 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Resmed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RME Stock 12 Month Forecast

Average Price Target

€206.68

▲(14.66% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Resmed in the last 3 months. The average price target is €206.68 with a high forecast of €276.41 and a low forecast of €183.98. The average price target represents a 14.66% change from the last price of €180.25.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"160":"€160","277":"€277","189.25":"€189.3","218.5":"€218.5","247.75":"€247.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":276.4065408,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€276.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":206.67670891636362,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€206.68</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":183.98310372,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€183.98</span>\n  </div></div>","useHTML":true}}],"tickPositions":[160,189.25,218.5,247.75,277],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,179.1,186.58511852307691,194.07023704615384,201.55535556923076,209.0404740923077,216.52559261538462,224.01071113846155,231.49582966153847,238.9809481846154,246.46606670769233,253.95118523076923,261.4363037538462,268.92142227692307,{"y":276.4065408,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,179.1,181.22128530125875,183.34257060251747,185.46385590377622,187.58514120503494,189.7064265062937,191.82771180755245,193.94899710881117,196.07028241006992,198.19156771132867,200.3128530125874,202.43413831384615,204.55542361510487,{"y":206.67670891636362,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,179.1,179.47562336307692,179.85124672615385,180.22687008923077,180.6024934523077,180.97811681538462,181.35374017846155,181.72936354153845,182.10498690461537,182.4806102676923,182.85623363076922,183.23185699384615,183.60748035692308,{"y":183.98310372,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":232.209,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":231.511,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":230.916,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":209.084,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":212.863,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.011,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":212.565,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":214.165,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.582,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.867,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.7,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.1,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€276.41

Average Price Target€206.68

Lowest Price Target€183.98

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jackson Philips

Rothschild & Co Redburn

Not Ranked

Rothschild & Co Redburn

€198.67

Hold

10.22%

Upside

Initiated

08/19/26

ResMed initiated with a Neutral at Rothschild & Co RedburnResMed initiated with a Neutral at Rothschild & Co Redburn

Anthony Petrone

Mizuho Securities

€190.03→€202.99

Buy

12.61%

Upside

Reiterated

08/11/26

Mizuho Securities Remains a Buy on Resmed (RMD)

Unknown Analyst

Oppenheimer

Not Ranked

Oppenheimer

―

Hold

―

Assigned

08/07/26

Oppenheimer Issues a Hold Rating on Resmed (RMD)

Adam Maeder

Piper Sandler

€194.35

Hold

7.82%

Upside

Reiterated

08/07/26

Piper Sandler Sticks to Its Hold Rating for Resmed (RMD)

Michael Matson

Needham

―

Hold

―

Reiterated

08/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Resmed (NYSE: RMD) and High Tide (NASDAQ: HITI)

David Rescott

Robert W. Baird

€187.44→€183.98

Hold

2.07%

Upside

Reiterated

08/07/26

ResMed price target lowered to $213 from $217 at BairdResMed price target lowered to $213 from $217 at Baird

Brett Fishbin

KeyBanc

€224.58→€220.26

Buy

22.20%

Upside

Reiterated

08/07/26

Analysts Conflicted on These Healthcare Names: Astrana Health (NASDAQ: ASTH), Resmed (NYSE: RMD) and Definium Therapeutics (NASDAQ: DFTX)

Craig Wong-Pan

RBC Capital

€202.12→€210.76

Hold

16.93%

Upside

Reiterated

08/07/26

RBC Capital Sticks to Their Hold Rating for Resmed (RMD)

Nathan Treybeck

Wells Fargo

€194.35→€185.71

Hold

3.03%

Upside

Assigned

08/07/26

Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Halozyme (NASDAQ: HALO) and Resmed (NYSE: RMD)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

08/07/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Resmed (NYSE: RMD) and DENTSPLY SIRONA (NASDAQ: XRAY)

Lyanne Harrison

Bank of America Securities

€276.41

Buy

53.35%

Upside

Reiterated

07/29/26

Bank of America Securities Keeps Their Buy Rating on Resmed (RMD)

David Bailey

Morgan Stanley

€198.67

Hold

10.22%

Upside

Reiterated

07/13/26

Resmed Maintained at Hold as Astral Ventilator Safety Notice Clouds Outlook; $230 Price Target Unchanged

Matthew Taylor

Jefferies

€194.35

Hold

7.82%

Upside

Reiterated

07/10/26

Jefferies Issues a Hold Rating on Resmed (RMD)

Laura Sutcliffe

Citi

€233.22→€202.99

Hold

12.61%

Upside

Downgraded

07/10/26

Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD) and Eli Lilly & Co (NYSE: LLY)

Jonathan Block

Stifel Nicolaus

€202.99

Hold

12.61%

Upside

Reiterated

07/08/26

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS), Meiragtx Holdings (NASDAQ: MGTX) and Resmed (NYSE: RMD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jackson Philips

Rothschild & Co Redburn

Not Ranked

Rothschild & Co Redburn

€198.67

Hold

10.22%

Upside

Initiated

08/19/26

ResMed initiated with a Neutral at Rothschild & Co RedburnResMed initiated with a Neutral at Rothschild & Co Redburn

Anthony Petrone

Mizuho Securities

€190.03→€202.99

Buy

12.61%

Upside

Reiterated

08/11/26

Mizuho Securities Remains a Buy on Resmed (RMD)

Unknown Analyst

Oppenheimer

Not Ranked

Oppenheimer

―

Hold

―

Assigned

08/07/26

Oppenheimer Issues a Hold Rating on Resmed (RMD)

Adam Maeder

Piper Sandler

€194.35

Hold

7.82%

Upside

Reiterated

08/07/26

Piper Sandler Sticks to Its Hold Rating for Resmed (RMD)

Michael Matson

Needham

―

Hold

―

Reiterated

08/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Resmed (NYSE: RMD) and High Tide (NASDAQ: HITI)

David Rescott

Robert W. Baird

€187.44→€183.98

Hold

2.07%

Upside

Reiterated

08/07/26

ResMed price target lowered to $213 from $217 at BairdResMed price target lowered to $213 from $217 at Baird

Brett Fishbin

KeyBanc

€224.58→€220.26

Buy

22.20%

Upside

Reiterated

08/07/26

Analysts Conflicted on These Healthcare Names: Astrana Health (NASDAQ: ASTH), Resmed (NYSE: RMD) and Definium Therapeutics (NASDAQ: DFTX)

Craig Wong-Pan

RBC Capital

€202.12→€210.76

Hold

16.93%

Upside

Reiterated

08/07/26

RBC Capital Sticks to Their Hold Rating for Resmed (RMD)

Nathan Treybeck

Wells Fargo

€194.35→€185.71

Hold

3.03%

Upside

Assigned

08/07/26

Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Halozyme (NASDAQ: HALO) and Resmed (NYSE: RMD)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

08/07/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Resmed (NYSE: RMD) and DENTSPLY SIRONA (NASDAQ: XRAY)

Lyanne Harrison

Bank of America Securities

€276.41

Buy

53.35%

Upside

Reiterated

07/29/26

Bank of America Securities Keeps Their Buy Rating on Resmed (RMD)

David Bailey

Morgan Stanley

€198.67

Hold

10.22%

Upside

Reiterated

07/13/26

Resmed Maintained at Hold as Astral Ventilator Safety Notice Clouds Outlook; $230 Price Target Unchanged

Matthew Taylor

Jefferies

€194.35

Hold

7.82%

Upside

Reiterated

07/10/26

Jefferies Issues a Hold Rating on Resmed (RMD)

Laura Sutcliffe

Citi

€233.22→€202.99

Hold

12.61%

Upside

Downgraded

07/10/26

Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD) and Eli Lilly & Co (NYSE: LLY)

Jonathan Block

Stifel Nicolaus

€202.99

Hold

12.61%

Upside

Reiterated

07/08/26

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS), Meiragtx Holdings (NASDAQ: MGTX) and Resmed (NYSE: RMD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

IMRXImmuneering

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Resmed

3 Months

Brett FishbinKeyBanc

Success Rate

9/15 ratings generated profit

Average Return

+1.89%

Copying Brett Fishbin's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +1.89% per trade.

1 Year

Lyanne HarrisonBank of America Securities

Success Rate

19/28 ratings generated profit

Average Return

+9.12%

Copying Lyanne Harrison's trades and holding each position for 1 Year would result in 67.86% of your transactions generating a profit, with an average return of +9.12% per trade.

2 Years

Lyanne HarrisonBank of America Securities

Success Rate

16/28 ratings generated profit

Average Return

+11.25%

Copying Lyanne Harrison's trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +11.25% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RME Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RME has received 14 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. RME average Analyst price target in the past 3 months is 206.68.

Each month's total comprises the sum of three months' worth of ratings.

RME Financial Forecast

RME Earnings Forecast

Next quarter’s earnings estimate for RME is €2.33 with a range of €2.25 to €2.41. The previous quarter’s EPS was €2.56. RME beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RME has Performed in-line its overall industry.

RME Sales Forecast

Next quarter’s sales forecast for RME is €1.21B with a range of €1.18B to €1.23B. The previous quarter’s sales results were €1.27B. RME beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RME has Performed in-line its overall industry.

RME Stock Forecast FAQ

What is DE:RME’s average 12-month price target, according to analysts?

Based on analyst ratings, Resmed’s 12-month average price target is 206.68.

What is DE:RME’s upside potential, based on the analysts’ average price target?

Resmed has 14.66% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Resmed a Buy, Sell or Hold?

Resmed has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 10 hold ratings and 0 sell ratings.

What is Resmed’s share price target?

The average share price target for Resmed is 206.68. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €276.41 ,and the lowest forecast is €183.98. The average share price target represents 14.66% Increase from the current price of €180.25.

What do analysts say about Resmed?

Resmed’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of Resmed?

To buy shares of DE:RME, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Resmed (RME) Stock Forecast & Price Target

RME Analyst Ratings

RME Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Resmed

RME Analyst Recommendation Trends

RME Financial Forecast

RME Earnings Forecast

RME Sales Forecast

RME Stock Forecast FAQ

Detailed List of Analyst Forecasts